Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
Abstract Relapse of FLT3‐mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.
Main Authors: | Rachel Brodie, Stephen E. Langabeer, John Quinn, Máirín E. McMenamin, Patrick J. Hayden |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-12-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.2487 |
Similar Items
-
Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation
by: Ya B Balzhanova, et al.
Published: (2019-08-01) -
Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature
by: Jayastu Senapati, et al.
Published: (2014-02-01) -
TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
by: Nico Gagelmann, et al.
Published: (2021-03-01) -
Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study
by: Ali Bazarbachi, et al.
Published: (2019-03-01) -
Leukemia cutis
by: Angoori G Rao, et al.
Published: (2012-01-01)